EBS Q4 2018 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$271M+39.7% YoY

Gross Profit

$108M40.0% margin

Operating Income

$11M4.1% margin

Net Income

-$4M-1.3% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+55.9%

Cash Flow

Operating Cash Flow

-$166M

Free Cash Flow

-$187M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.2B

Stockholders' Equity

$1.0B

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$271M	$194M	+39.7%
Gross Profit	$108M	$110M	-1.1%
Operating Income	$11M	$53M	-78.9%
Net Income	-$4M	$34M	-110.3%

Geographic Segments

UNITED STATES

$163M100%